[go: up one dir, main page]

WO2006113471A3 - Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle - Google Patents

Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle Download PDF

Info

Publication number
WO2006113471A3
WO2006113471A3 PCT/US2006/014139 US2006014139W WO2006113471A3 WO 2006113471 A3 WO2006113471 A3 WO 2006113471A3 US 2006014139 W US2006014139 W US 2006014139W WO 2006113471 A3 WO2006113471 A3 WO 2006113471A3
Authority
WO
WIPO (PCT)
Prior art keywords
nmda
azacycloalkyl
alkyl
nr2b antagonists
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/014139
Other languages
English (en)
Other versions
WO2006113471A2 (fr
Inventor
Mark E Layton
Kevin J Rodzinak
Michael J Kelly Iii
Philip E Sanderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US11/918,336 priority Critical patent/US20090124600A1/en
Priority to CA002603876A priority patent/CA2603876A1/fr
Priority to JP2008507751A priority patent/JP2008536927A/ja
Priority to EP06750229A priority patent/EP1874318A2/fr
Priority to AU2006236625A priority patent/AU2006236625A1/en
Publication of WO2006113471A2 publication Critical patent/WO2006113471A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006113471A3 publication Critical patent/WO2006113471A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I) et/ou des sels, des énantiomères individuels et des stéréoisomères de ceux-ci, acceptables d'un point de vue pharmaceutique, qui sont efficaces comme antagonistes de NMDA/NR2B, utilisés pour traiter des pathologies comme la douleur, la maladie de Parkinson, la maladie d'Alzheimer, l'épilepsie, la dépression, l'anxiété et les lésions cérébrales d'origine ischémique, par exemple l'accident vasculaire cérébral.
PCT/US2006/014139 2005-04-19 2006-04-14 Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle Ceased WO2006113471A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/918,336 US20090124600A1 (en) 2005-04-19 2006-04-14 N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
CA002603876A CA2603876A1 (fr) 2005-04-19 2006-04-14 Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle
JP2008507751A JP2008536927A (ja) 2005-04-19 2006-04-14 Ｎ−アルキル−アザシクロアルキルｎｍｄａ／ｎｒ２ｂ拮抗物質
EP06750229A EP1874318A2 (fr) 2005-04-19 2006-04-14 Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle
AU2006236625A AU2006236625A1 (en) 2005-04-19 2006-04-14 N-alkyl-azacycloalkyl NMDA/NR2B antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67263905P 2005-04-19 2005-04-19
US60/672,639 2005-04-19

Publications (2)

Publication Number Publication Date
WO2006113471A2 WO2006113471A2 (fr) 2006-10-26
WO2006113471A3 true WO2006113471A3 (fr) 2007-12-13

Family

ID=37115748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014139 Ceased WO2006113471A2 (fr) 2005-04-19 2006-04-14 Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle

Country Status (6)

Country Link
EP (1) EP1874318A2 (fr)
JP (1) JP2008536927A (fr)
CN (1) CN101163482A (fr)
AU (1) AU2006236625A1 (fr)
CA (1) CA2603876A1 (fr)
WO (1) WO2006113471A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129417B2 (en) 2008-11-26 2012-03-06 Abbott Laboratories Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
US8691865B2 (en) 2008-11-26 2014-04-08 Abbvie Inc. Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
WO2013135674A1 (fr) * 2012-03-12 2013-09-19 Syngenta Participations Ag Composés de 2-aryl-acétamide insecticides
CA2869216A1 (fr) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methodes de traitement de la maladie de parkinson
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
CN106795163B (zh) * 2014-06-04 2019-07-30 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的二氟乙基吡啶衍生物
KR102569031B1 (ko) 2014-09-15 2023-08-22 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 피롤로피리미딘 유도체
WO2016049048A1 (fr) * 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Traitement des troubles de l'anxiété et des troubles du spectre autistique
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EP3253761A4 (fr) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b
WO2016196513A1 (fr) 2015-06-01 2016-12-08 Rugen Holdings (Cayman) Limited Composés hétérocycliques 3,3-difluoropipéridine carbamate utilisés en tant qu'antagonistes des récepteurs nmda nr2b
EP3383429B1 (fr) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Antagonistes du recepteur au nmda pour le traitement de l'angiogenèse tumorale
WO2018098128A1 (fr) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété
JP7306392B2 (ja) * 2018-07-31 2023-07-11 小野薬品工業株式会社 ベンゼン誘導体
WO2020196828A1 (fr) * 2019-03-28 2020-10-01 武田薬品工業株式会社 Composé hétérocyclique contenant de l'azote
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
EP3980401A1 (fr) 2019-06-04 2022-04-13 Boehringer Ingelheim International GmbH Dérivés de purine, utilisés en tant que modulateurs négatifs de nr2b et leur utilisation en tant que médicament, en particulier pour le traitement de troubles dépressifs
WO2022241188A1 (fr) * 2021-05-14 2022-11-17 Theravance Biopharma R&D Ip, Llc Synthèse énantiosélective d'un composé aminotropane

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017409A2 (fr) * 2004-08-03 2006-02-16 Merck & Co., Inc. Antagonistes de nmda/nr2b à base d'hétéroaryles 1,3-disubstitués

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017409A2 (fr) * 2004-08-03 2006-02-16 Merck & Co., Inc. Antagonistes de nmda/nr2b à base d'hétéroaryles 1,3-disubstitués

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129417B2 (en) 2008-11-26 2012-03-06 Abbott Laboratories Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers

Also Published As

Publication number Publication date
WO2006113471A2 (fr) 2006-10-26
EP1874318A2 (fr) 2008-01-09
CN101163482A (zh) 2008-04-16
CA2603876A1 (fr) 2006-10-26
JP2008536927A (ja) 2008-09-11
AU2006236625A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2006113471A3 (fr) Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle
WO2006017409A3 (fr) Antagonistes de nmda/nr2b à base d'hétéroaryles 1,3-disubstitués
MX2010007588A (es) Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor de esfingosina-1-fosfato (s1p).
CL2008003787A1 (es) Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.
ZA200804498B (en) N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CA2527093A1 (fr) 3-fluoro-piperidines en tant qu'antagonistes de nmda/nr2b
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2010088408A3 (fr) Antagonistes du récepteur nmda, sélectifs pour des sous-unités, et destinés au traitement d'états neurologiques
WO2010039186A3 (fr) Composés utiles en tant que modulateurs de la faah et leurs utilisations
WO2010033543A3 (fr) Composés inédits utilisables en tant que ligands des récepteurs cannabinoïdes
WO2008104386A3 (fr) Méthode de traitement d'amyloïdoses
NO20073760L (no) Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
JO2769B1 (en) Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007150010A3 (fr) Dérivés de cyclopropylamines
WO2007107442A3 (fr) Derives de bis 1,2,3,4-tetrahydroisoquinoline et utilisation de ces derniers en tant que substances pharmaceutiques
WO2009148290A3 (fr) Composés de propanamine à substitution 3
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
WO2007047394A3 (fr) Derives de thiotriazolyle
WO2009148291A3 (fr) Composés de pipéridine à substitution 3 ou 4
CL2007003275A1 (es) Compuestos derivados de 4-imidazoles sustituidos; proceso de preparacion; medicamento; y uso para el tratamiento de depresion, trastornos de ansiedad, trastornos psicoticos, esquizofrenia, enfermedad de parkinson, migrana, entre otras.
WO2014144500A3 (fr) Procédés de synthèse d'un analogue difluorolactam

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680012726.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006236625

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4217/CHENP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2603876

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11918336

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2006236625

Country of ref document: AU

Date of ref document: 20060414

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006750229

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008507751

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU